Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 185

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 185
---
 the Compliance Period, in accordance with Nasdaq rules. On April 30, 2025, the Company received notice from
Nasdaq that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).

As a result
of the Reverse Stock Split, the Company’s outstanding Common Stock was reduced from approximately 243,312,885 shares to approximately 6,951,671 shares, based on the number of shares of Common Stock outstanding as of April 14, 2025. All
share and per share information in this prospectus has been retroactively adjusted to reflect the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Instead, each fractional share remaining after
completion of the reverse share split that was less than a whole share was rounded down and canceled in exchange for an amount in cash (without interest or deduction) equal to the fraction of one share to which such stockholder would otherwise be
entitled multiplied by the closing price of the Common Stock on The Nasdaq Capital Market on the last trading day immediately preceding the effectiveness of the Reverse Stock Split. The Reverse Stock Split was applied to all the Company’s
outstanding Common Stock and therefore did not affect any shareholder’s ownership percentage of the shares, except for changes as a result of the elimination of fractional shares. The Reverse Stock Split did not alter the voting rights attached
to the shares.

Sorrento Chapter 11 Filing

On February 13, 2023, Sorrento Therapeutics, Inc. (“Sorrento”), together with its wholly owned direct subsidiary, Scintilla
Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). The Chapter 11 proceedings are
jointly administered under the caption In re Sorrento Therapeutics, Inc., et al, Case Number 23-90085 (DRJ) (the “Chapter 11 Cases”). While we were previously majority-owned by Sorrento, we were not
a debtor in Sorrento’s voluntary Chapter 11 filing. Pursuant to that

115

certain Stock Purchase Agreement that we entered into with Sorrento on September 21, 2023 (the “Sorrento SPA”), we repurchased shares of our Common Stock and Series A Preferred Stock from Sorrento. As a result, Sorrento no longer